Loading...

PE anti-human CD62L Antibody

Pricing & Availability
Clone
DREG-56 (See other available formats)
Regulatory Status
RUO
Workshop
V S056
Other Names
L-selectin, LECAM-1, LAM-1, Leu-8, TQ-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
DREG-56
Human peripheral blood lymphocytes stained with DREG-56 PE
  • DREG-56
    Human peripheral blood lymphocytes stained with DREG-56 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
304805 25 tests 79€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304840 100 µg 185€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304806 100 tests 190€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Concentrated supernatant from PMA-activated human peripheral blood leukocytes
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: Western blotting2,3,9 and in vitro blocking of lymphocytes binding to high endothelial venules (HEV)2. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 304853-304858).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Kishimoto TK, et al. 1990. Proc. Natl. Acad. Sci. USA 87:2244. (WB, Block)
  3. Jutila M, et al. 2002. J. Immunol. 169:1768. (WB)
  4. Tamassia N, et al. 2008. J. Immunol. 181:6563. (FC) PubMed
  5. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Koenig JM, et al. 1996. Pediatr. Res. 39:616. (WB)
  10. Shi C, et al. 2011. J. Immunol. 187:5293. (FC) PubMed
  11. Burges M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
  12. Cash JL, et al. 2013. EMBO Rep. 14:999. (FC) PubMed
Product Citations
  1. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  2. Anderson NR, et al. 2019. Cell Adh Migr. 13:163. PubMed
  3. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  4. Uniken Venema WT, et al. 2019. Gastroenterology. 156:812. PubMed
  5. Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
  6. Magri G et al. 2017. Immunity. 47(1):118-134 . PubMed
  7. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  8. Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
  9. Burgess M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
  10. Groen B, et al. 2015. Sci Rep. 5: 13618. PubMed
  11. Liu B, et al. 2015. J Virol. 89: 11834 - 11844. PubMed
  12. He Z, et al. 2016. Exp Hematol. 44:161-165. PubMed
  13. Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
  14. Messerer DAC, et al. 2020. Front Immunol. 11:571992. PubMed
  15. Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
  16. Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
  17. Ye Z, et al. 2021. NPJ Aging Mech Dis. 7:4. PubMed
  18. Ye Z, et al. 2021. Nat Commun. 12:907. PubMed
  19. Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
  20. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  21. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  22. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  23. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  24. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  25. Hug S, et al. 2021. Front Immunol. 12:642867. PubMed
  26. Sung BY, et al. 2022. J Clin Invest. 132:. PubMed
  27. Gatla H, et al. 2022. Front Med Technol. 4:850565. PubMed
  28. Bonte S, et al. 2021. Oncoimmunology. 10:1954800. PubMed
  29. Carnevale J, et al. 2022. Nature. 609:174. PubMed
  30. Johnson AJ, et al. 2021. Cancer Immunol Res. 9:1047. PubMed
  31. Tokatlian T, et al. 2022. J Immunother Cancer. 10:. PubMed
  32. Wu B, et al. 2022. Nat Commun. 13:2155. PubMed
  33. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  34. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  35. Li L, et al. 2022. FEBS J. 289:2877. PubMed
  36. Wohlgemuth L, et al. 2022. Cells. 11: . PubMed
  37. Guo A, et al. 2022. Nature. 607:135. PubMed
  38. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  39. Chen J, et al. 2023. Cell Res. 33:341. PubMed
RRID
AB_314465 (BioLegend Cat. No. 304805)
AB_2564163 (BioLegend Cat. No. 304840)
AB_314466 (BioLegend Cat. No. 304806)

Antigen Details

Structure
Selectin, single chain glycoprotein, 74-95 kD
Distribution

Majority of B cells, naïve T cells, subset of memory T and NK cells, monocytes, granulocytes, thymocytes

Function
Leukocyte homing, leukocyte tethering, rolling
Ligand/Receptor
CD34, GlyCAM, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Thymocytes, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References
  1. Kishimoto T, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
  2. Kishimoto T, et al. 1991. Blood 78:805.

 

Gene ID
6402 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 05.21.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account